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‘P4’ medicine
Systems  or  ‘P4’  medicine  offers  a  grand  vision  for 
achieving  better  population  health.  The  four  Ps  - 
predictive,  preventive,  personalized  and  participatory  - 
invoke a patient-centered approach that prioritizes health 
promotion  over  disease  treatment.  In  this  issue  of 
Genome Medicine, Bousquet and co-authors [1] suggest 
that  this  approach  will  be  especially  suitable  for  non-
communicable diseases (NCDs), conditions such as heart 
disease,  cancer  and  diabetes  that  represent  large  and 
growing public health burdens. Their optimism is based 
on an increasing array of molecular tools to investigate 
biological systems at an unprecedented level of precision. 
The authors call for population-based research aimed at 
understanding  how  NCDs  ‘cluster  at  the  genetic, 
molecular (and) mechanistic levels and are affected by 
environmental and social factors’; the anticipated result 
is  a  redesigned  healthcare  system  that  identifies  early 
disease  and  delivers  beneficial,  cost-effective  inter  ven-
tions. The potential benefits of this research paradigm are 
impressive - but closer inspection suggests that caution is 
in order.
As  Bousquet  and  colleagues  observe,  most  common 
diseases  have  a  complex  etiology  that  includes  host, 
environmental and social determinants, acting across the 
lifespan. In particular, social conditions such as poverty, 
substandard  housing  and  restricted  access  to  employ-
ment and education are strongly associated with negative 
health  outcomes  [2-4].  How  adverse  social  conditions 
contribute  to  disease  remains  poorly  understood;  if 
systems biology can elucidate this relationship, it might 
lead to welcome new strategies for prevention or early 
treatment.  Such  developments  would  represent  an 
important advance. However, P4 medicine cannot solve 
the root problem: the need for political and public health 
action  to  improve  the  life  chances  of  disadvantaged 
people [2]. In this context, a realistic assessment of the 
prospects for systems biology is sorely needed.
Weighing the contributions of P4 medicine
A central component of the P4 medicine vision is that an 
array of new biomarkers will identify diseases at early, 
treatable  stages,  enabling  effective  prevention  of  mor-
bidity and mortality. This approach is intuitively appeal-
ing. Early detection already offers important life-saving 
opportunities - for example, mammography and phenyl-
ketonuria screening. But early detection has its failures as 
well. Newborn screening for neuroblastoma, for example, 
increased detection rates but had no impact on disease 
mortality [5] - and led to iatrogenic harm (that is, injury 
through  medical  treatment):  screening  missed  some 
severe cases, and found others whose relatively benign 
course did not require early treatment [5]. Similarly, the 
use of the prostate-specific antigen test for early detec-
tion of prostate cancer is associated with limited mor-
tality benefit and significant harm, including impotence 
and incontinence, due to overtreatment of latent cancers 
[6,7].
The  reason  for  these  difficulties  is  not  hard  to  find: 
screening is complicated by false-positive/false-negative 
results  (screening  may  suggest  a  condition  that  is  not 
present, or fail to identify a condition that is); lead time 
bias (screening may identify a disease early without pro-
longing  survival);  length  bias  (screening  may  dispro-
portionately  identify  less-aggressive,  slower-progressing 
disease); and overdiagnosis (identification of early disease 
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© 2011 BioMed Central Ltdin people whose course would be benign if left untreated) 
[6]. These problems, and in particular limited predictive 
value  and  overdiagnosis,  are  likely  outcomes  for  bio-
markers associated with NCDs because of the variable 
course  of  these  conditions  and  the  important  contri-
bution  of  social  and  lifestyle  factors  to  outcome  [2,3]. 
Undoubtedly, systems biology will help to refine screen-
ing protocols, and some P4 biomarkers will have suffi-
cient predictive value to improve care, but past screening 
experience tells us that none will be fully error free [6].
As with biomarkers, systems biology offers promise for 
drug  discovery  [1].  However,  drug  development  is 
notoriously  difficult:  predictive  models  are  theoretical 
and do not always withstand testing; animal models are 
an inexact facsimile of human biology; and targeting one 
part  of  a  given  pathway  may  have  unforeseen  effects 
elsewhere. Systems biology is likely to make important 
contributions, but progress will still be slow because a 
large complement of targeted therapeutics will be needed 
for substantive healthcare improvement.
The prospects are less clear for a P4 contribution to 
health behaviors. Although some effective strategies for 
improving health behaviors are emerging [8], the role of 
biomarker-based  behavioral  change  appears  limited. 
DNA-based risk prediction, for example, appears to have 
little  or  no  effect  on  health  behaviors  [9]  -  and  social 
conditions represent formidable barriers. A patient who 
faces difficulty housing or feeding her children is unlikely 
to  spend  resources  addressing  a  possible  future  health 
risk. Likewise, using P4 profiling to encourage intake of 
green, leafy vegetables is of limited value for a patient 
living  on  the  northern  tundra  or  in  an  inner-city 
neighborhood with no gardens or grocery stores. Solving 
these problems will require efforts beyond the realms of 
biomedical research and health care.
P4 medicine and research participation
Achieving  the  benefits  of  systems  biology  will  require 
substantial  research  participation  and  investment  in 
research infrastructure. Bousquet and colleagues propose 
that  individuals  have  a  ‘societal  responsibility  to  make 
their anonymized data available to appropriate scientists 
and  physicians’  in  order  to  accomplish  the  research 
necessary  for  P4  medicine.  Certainly  the  inclusion  of 
diverse populations will be necessary to ensure that the 
benefits of research are broadly relevant [10].
In the absence of the political will to address poverty 
and other social conditions associated with poor health 
outcomes,  many  people  will  continue  to  have  limited 
access  to  effective  health  care  and  therefore  little 
motivation to participate in research aimed at improving 
it. The argument that they have an obligation to do so is 
difficult to justify when there is no assurance that they - 
or their descendants - will reap the benefits. Accordingly, 
Bousquet  and  colleagues  call  for  increased  efforts  to 
address the social determinants of health, arguing that 
‘P4 medicine development should be a global aim and not 
a privilege of ‘rich’ countries.’ Beyond moral exhortation, 
biomedical researchers face the serious question of how 
to engage with this dilemma.
The way forward
What can researchers do to encourage increased research 
participation  based  on  reasonable  expectations?  And 
how can they contribute to broader efforts to improve 
health  equity?  An  important  starting  point  is  to  avoid 
suggesting  that  P4  medicine  will  provide  the  much-
wished-for  magic  bullet.  Policy  makers  would  un-
doubtedly  welcome  a  technological  fix  to  population 
health. Researchers must avoid overpromising, and instead 
should  counsel  policy  makers  that  efforts  to  improve 
social  conditions  have  a  greater  potential  to  enhance 
population  health  than  even  the  most  optimistic 
projections for P4 medicine.
Systems biology is poised to provide a wealth of new 
knowledge  about  human  health  and  disease.  Oppor-
tunities for improving health care will emerge, and these 
are  reason  enough  to  celebrate  the  systems  biology 
approach - but they will not solve the tough social issues 
that  lie  at  the  center  of  population  health  challenges. 
Bousquet and colleagues have it right when they link P4 
medicine to a call to address social inequities. In doing 
so,  they  acknowledge  the  limitations  of  biomedical 
research  and  the  importance  of  thinking  beyond  bio-
logical  systems  to  the  political,  psychological,  socio-
cultural and economic realities that shape them.
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